# ENLIVEN THERAPEUTICS INC (ELVN)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/ELVN/

- Reporting holders: 4
- Reported value: $139.2K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $73.9K | 1,613 | 0.0% | 9 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $35.8K | 780 | 0.0% | 12 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $20.5K | 447 | 0.0% | 12 |
| [MassMutual Private Wealth & Trust, FSB](https://holderbook.com/funds/1103653-massmutual-private-wealth-trust-fsb/) | $9.0K | 197 | 0.0% | 7 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 4 | $139.2K |
| Q2 2026 | 217 | $4.3B |
| Q1 2026 | 172 | $2.5B |
| Q4 2025 | 125 | $961.8M |
| Q3 2025 | 132 | $1.2B |
| Q2 2025 | 124 | $1.2B |
| Q1 2025 | 121 | $983.9M |
| Q4 2024 | 112 | $1.1B |
| Q3 2024 | 100 | $1.2B |
| Q2 2024 | 92 | $1.1B |
| Q1 2024 | 72 | $783.3M |
| Q4 2023 | 61 | $541.2M |